Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP4345 in schizophrenia
NCT02720263Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP4345 in schizophrenia (3 arms), sponsored by Astellas Pharma. Primary endpoints: Safety and tolerability assessed as nature, frequency and severity of adverse events, Change from baseline in supine blood pressure at Day 21 and 32 more. Started Mar 2016; status: completed.
02
Drugs
ASP4345
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02720263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720263.